Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orexo has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Rapinyl, for breakthrough cancer pain.
Subscribe to our email newsletter
ProStrakan Group, an international speciality pharmaceutical is Orexo’s exclusive partner for sales and marketing of Abstral/Rapinyl in Europe. Abstral/Rapinyl will be launched in Sweden in the third quarter of 2008, and across Europe from the end of 2008 under the brand name Abstral.
Torbjorn Bjerke, president and CEO of Orexo, said: “The approval is a fantastic achievement for Orexo and our ability to become a profitable pharmaceutical company. I believe that Abstral will play a major role in the treatment of cancer patients suffering from breakthrough pain.”